{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:58:00Z","timestamp":1793923080872,"version":"4.8.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Meropenem\/vaborbactam (M\/V) and ceftazidime\/avibactam (C\/A) are considered key agents in treating KPC-producing\n                      <jats:italic>Klebsiella pneumoniae (Kp)<\/jats:italic>\n                      infections. We compared these two drugs in ICUs patients with BSI and\/or pneumoniae due to KPC- Kp.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective multicentre study analysed ICU patients with bloodstream infections (BSI) and\/or pneumonia caused by KPC-Kp across five Italian ICUs from January 2021 to December 2023. Propensity-score matching (PSM) was applied to mitigate the impact of confounding factors. The primary outcome was 30-day all-cause mortality. Secondary outcomes included early clinical improvement at 72\u00a0h, computing the odds ratio (OR) as effect size, and infection-related events. Subgroup analyses were performed based on relevant prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 177 patients, with 88 subjects paired after-matching (52 treated with C\/A and 36 with M\/V). As for primary outcome, after PSM, no statistically significant differences in 30-day mortality were observed between the two groups: in the Kaplan-Meier survival log-rank test was\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.38, and PSM-adjusted HR of M\/V on mortality was 0.65 (95% CI 0.55\u20131.68). As for secondary outcomes, M\/V significantly improved early clinical response post-PSM (OR: 2.19, 95% CI: 1.35\u20133.55).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>M\/V showed no statistically significant difference in 30-day mortality compared to C\/A but demonstrated significantly improved in early clinical response for patients with KPC-Kp. These findings were consistent between unmatched and matched patients. Further prospective studies are warranted to validate these observations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-025-02608-7","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:58:25Z","timestamp":1752670705000},"page":"2645-2658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Head-to-head: meropenem\/vaborbactam versus ceftazidime\/avibactam in ICUs patients with KPC-producing K. pneumoniae infections\u2013 results from a retrospective multicentre study"],"prefix":"10.1007","volume":"53","author":[{"given":"Andrea","family":"Marino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Enrico","family":"Maraolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Mazzitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Geremia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Vito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Gullotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Vania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lo Menzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Navalesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Volpicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Fiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Prestifilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio Maria","family":"Mastroianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giordano","family":"Madeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cacopardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Nunnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"2608_CR1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/antibiotics12071169","volume":"12","author":"A Marino","year":"2023","unstructured":"Marino A, Pulvirenti S, Campanella E, Stracquadanio S, Ceccarelli M, Micali C, Tina LG, Di Dio G, Stefani S, Cacopardo B, et al. Ceftazidime-Avibactam treatment for Klebsiella Pneumoniae bacteremia in preterm infants in NICU: A clinical experience. Antibiot (Basel). 2023;12:1169. https:\/\/doi.org\/10.3390\/antibiotics12071169.","journal-title":"Antibiot (Basel)"},{"key":"2608_CR2","doi-asserted-by":"publisher","first-page":"ofae273","DOI":"10.1093\/ofid\/ofae273","volume":"11","author":"M Tumbarello","year":"2024","unstructured":"Tumbarello M, Raffaelli F, Giannella M, De Pascale G, Cascio A, De Rosa FG, Cattelan AM, Oliva A, Saracino A, Bassetti M, et al. Outcomes and predictors of mortality in patients with KPC-Kp infections treated with meropenem vaborbactam: an observational multicenter study. Open Forum Infect Dis. 2024;11:ofae273. https:\/\/doi.org\/10.1093\/ofid\/ofae273.","journal-title":"Open Forum Infect Dis"},{"key":"2608_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jgar.2019.06.009","volume":"20","author":"DR Giacobbe","year":"2020","unstructured":"Giacobbe DR, Saffioti C, Losito AR, Rinaldi M, Aurilio C, Bolla C, Boni S, Borgia G, Carannante N, Cassola G, et al. Use of colistin in adult patients: A Cross-Sectional study. J Glob Antimicrob Resist. 2020;20:43\u20139. https:\/\/doi.org\/10.1016\/j.jgar.2019.06.009.","journal-title":"J Glob Antimicrob Resist"},{"key":"2608_CR4","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1093\/jac\/dkad262","volume":"78","author":"DR Giacobbe","year":"2023","unstructured":"Giacobbe DR, Marelli C, Cattardico G, Fanelli C, Signori A, Di Meco G, Di Pilato V, Mikulska M, Mazzitelli M, Cattelan AM, et al. Mortality in KPC-Producing Klebsiella Pneumoniae bloodstream infections: A changing landscape. J Antimicrob Chemother. 2023;78:2505\u201314. https:\/\/doi.org\/10.1093\/jac\/dkad262.","journal-title":"J Antimicrob Chemother"},{"key":"2608_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, Vazquez J, Zaitsev V, Bidair M, Chorvat E, et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319:788. https:\/\/doi.org\/10.1001\/jama.2018.0438.","journal-title":"JAMA"},{"key":"2608_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3390\/antibiotics10050536","volume":"10","author":"P Gaibani","year":"2021","unstructured":"Gaibani P, Lombardo D, Bussini L, Bovo F, Munari B, Giannella M, Bartoletti M, Viale P, Lazzarotto T, Ambretti S. Epidemiology of meropenem\/vaborbactam resistance in KPC-Producing Klebsiella Pneumoniae causing bloodstream infections in Northern italy, 2018. Antibiotics. 2021;10:536. https:\/\/doi.org\/10.3390\/antibiotics10050536.","journal-title":"Antibiotics"},{"key":"2608_CR7","doi-asserted-by":"publisher","first-page":"106679","DOI":"10.1016\/j.ijantimicag.2022.106679","volume":"60","author":"Y-L Lee","year":"2022","unstructured":"Lee Y-L, Ko W-C, Hsueh P-R. Geographic patterns of global isolates of Carbapenem-Resistant Klebsiella Pneumoniae and the activity of ceftazidime\/avibactam, meropenem\/vaborbactam, and comparators against these isolates: results from the antimicrobial testing leadership and surveillance (ATLAS) program, 2020. Int J Antimicrob Agents. 2022;60:106679. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106679.","journal-title":"Int J Antimicrob Agents"},{"key":"2608_CR8","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.3390\/antibiotics12101521","volume":"12","author":"A Marino","year":"2023","unstructured":"Marino A, Campanella E, Stracquadanio S, Calvo M, Migliorisi G, Nicolosi A, Cosentino F, Marletta S, Spampinato S, Prestifilippo P, et al. Ceftazidime\/Avibactam and meropenem\/vaborbactam for the management of enterobacterales infections: A narrative review, clinical considerations, and expert opinion. Antibiot (Basel). 2023;12:1521. https:\/\/doi.org\/10.3390\/antibiotics12101521.","journal-title":"Antibiot (Basel)"},{"key":"2608_CR9","doi-asserted-by":"publisher","first-page":"dlac121","DOI":"10.1093\/jacamr\/dlac121","volume":"4","author":"A Oliva","year":"2022","unstructured":"Oliva A, Volpicelli L, Di Bari S, Curtolo A, Borrazzo C, Cogliati Dezza F, Cona A, Agrenzano S, Mularoni A, Trancassini M, et al. Effect of ceftazidime\/avibactam plus fosfomycin combination on 30\u2005day mortality in patients with bloodstream infections caused by KPC-Producing Klebsiella pneumoniae: results from a multicentre retrospective study. JAC-Antimicrobial Resist. 2022;4:dlac121. https:\/\/doi.org\/10.1093\/jacamr\/dlac121.","journal-title":"JAC-Antimicrobial Resist"},{"key":"2608_CR10","doi-asserted-by":"publisher","unstructured":"Ackley R, Roshdy D, Meredith J, Minor S, Anderson WE, Capraro GA, Polk C. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for treatment of Carbapenem-Resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2020;64. https:\/\/doi.org\/10.1128\/aac.02313-19.","DOI":"10.1128\/aac.02313-19"},{"key":"2608_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/antibiotics14010029","volume":"14","author":"MD Zilberberg","year":"2025","unstructured":"Zilberberg MD, Nathanson BH, Redell MA, Sulham K, Shorr AF. Comparative outcomes of Meropenem\u2013Vaborbactam vs. Ceftazidime\u2013Avibactam among adults hospitalized with an infectious syndrome in the US, 2019\u20132021. Antibiotics. 2025;14:29. https:\/\/doi.org\/10.3390\/antibiotics14010029.","journal-title":"Antibiotics"},{"key":"2608_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"key":"2608_CR13","doi-asserted-by":"publisher","unstructured":"Moreno R, Rhodes A, Piquilloud L, Hernandez G, Takala J, Gershengorn HB, Tavares M, Coopersmith CM, Myatra SN, Singer M, et al. The sequential organ failure assessment (SOFA) score: has the time come for an update?? Crit Care. 2023;27. https:\/\/doi.org\/10.1186\/s13054-022-04290-9.","DOI":"10.1186\/s13054-022-04290-9"},{"key":"2608_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13:818\u201329.","journal-title":"Crit Care Med"},{"key":"2608_CR15","unstructured":"EU Case Definitions Available online. https:\/\/www.ecdc.europa.eu\/en\/all-topics\/eu-case-definitions (accessed on 19 November 2024)."},{"key":"2608_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E Jong","year":"2016","unstructured":"Jong, E. de; Oers, J.A. van; Beishuizen, A.; Vos, P.; Vermeijden, W.J.; Haas, L.E.; Loef, B.G.; Dormans, T.; Melsen, G.C. van; Kluiters, Y.C.; et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, Open-Label trial. Lancet Infect Dis. 2016;16:819\u201327. https:\/\/doi.org\/10.1016\/S1473-3099(16)00053-0.","journal-title":"Lancet Infect Dis"},{"key":"2608_CR17","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2020.6348","volume":"323","author":"E von Dach","year":"2020","unstructured":"von Dach E, Albrich WC, Brunel A-S, Prendki V, Cuvelier C, Flury D, Gayet-Ageron A, Huttner B, Kohler P, Lemmenmeier E, et al. Effect of C-Reactive Protein\u2013Guided antibiotic treatment duration, 7-Day treatment, or 14-Day treatment on 30-Day clinical failure rate in patients with uncomplicated Gram-Negative bacteremia: A randomized clinical trial. JAMA. 2020;323:2160\u20139. https:\/\/doi.org\/10.1001\/jama.2020.6348.","journal-title":"JAMA"},{"key":"2608_CR18","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b","volume":"17","author":"RB D\u2019Agostino","year":"1998","unstructured":"D\u2019Agostino RB. Propensity score methods for Bias reduction in the comparison of a treatment to a Non-Randomized control group. Stat Med. 1998;17:2265\u201381. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b.","journal-title":"Stat Med"},{"key":"2608_CR19","doi-asserted-by":"publisher","first-page":"ofac110","DOI":"10.1093\/ofid\/ofac110","volume":"9","author":"AM Eikenboom","year":"2022","unstructured":"Eikenboom AM, Le Cessie S, Waernbaum I, Groenwold RHH, de Boer MGJ. Quality of conduct and reporting of propensity score methods in studies investigating the effectiveness of antimicrobial therapy. Open Forum Infect Dis. 2022;9:ofac110. https:\/\/doi.org\/10.1093\/ofid\/ofac110.","journal-title":"Open Forum Infect Dis"},{"key":"2608_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","volume":"113","author":"F Li","year":"2018","unstructured":"Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113:390\u2013400. https:\/\/doi.org\/10.1080\/01621459.2016.1260466.","journal-title":"J Am Stat Assoc"},{"key":"2608_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJM198707163170304","volume":"317","author":"B Freedman","year":"1987","unstructured":"Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141\u20135. https:\/\/doi.org\/10.1056\/NEJM198707163170304.","journal-title":"N Engl J Med"},{"key":"2608_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12874-020-00994-0","volume":"20","author":"E Granger","year":"2020","unstructured":"Granger E, Watkins T, Sergeant JC, Lunt MA. Review of the use of propensity score diagnostics in papers published in High-Ranking medical journals. BMC Med Res Methodol. 2020;20:132. https:\/\/doi.org\/10.1186\/s12874-020-00994-0.","journal-title":"BMC Med Res Methodol"},{"key":"2608_CR23","doi-asserted-by":"publisher","first-page":"16","DOI":"10.21037\/atm.2018.12.10","volume":"7","author":"Z Zhang","year":"2019","unstructured":"Zhang Z, Kim HJ, Lonjon G, Zhu Y. Written on behalf of AME Big-Data clinical trial collaborative group balance diagnostics after propensity score matching. Ann Transl Med. 2019;7:16. https:\/\/doi.org\/10.21037\/atm.2018.12.10.","journal-title":"Ann Transl Med"},{"key":"2608_CR24","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for Propensity-Score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150\u201361. https:\/\/doi.org\/10.1002\/pst.433.","journal-title":"Pharm Stat"},{"key":"2608_CR25","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/rssb.12027","volume":"76","author":"K Imai","year":"2014","unstructured":"Imai K, Ratkovic M. Covariate balancing propensity score. J Royal Stat Soc Ser B: Stat Methodol. 2014;76:243\u201363. https:\/\/doi.org\/10.1111\/rssb.12027.","journal-title":"J Royal Stat Soc Ser B: Stat Methodol"},{"key":"2608_CR26","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/aje\/kwy049","volume":"187","author":"SV Wang","year":"2018","unstructured":"Wang SV, Jin Y, Fireman B, Gruber S, He M, Wyss R, Shin H, Ma Y, Keeton S, Karami S, et al. Relative performance of propensity score matching strategies for subgroup analyses. Am J Epidemiol. 2018;187:1799\u2013807. https:\/\/doi.org\/10.1093\/aje\/kwy049.","journal-title":"Am J Epidemiol"},{"key":"2608_CR27","doi-asserted-by":"publisher","unstructured":"Ali MS, Prieto-Alhambra D, Lopes LC, Ramos D, Bispo N, Ichihara MY, Pescarini JM, Williamson E, Fiaccone RL, Barreto ML, et al. Propensity score methods in health technology assessment: principles, extended applications, and recent advances. Front Pharmacol. 2019;10. https:\/\/doi.org\/10.3389\/fphar.2019.00973.","DOI":"10.3389\/fphar.2019.00973"},{"key":"2608_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-Value. Ann Intern Med. 2017;167:268\u201374. https:\/\/doi.org\/10.7326\/M16-2607.","journal-title":"Ann Intern Med"},{"key":"2608_CR29","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/jac\/dkaa492","volume":"76","author":"C Tsioutis","year":"2021","unstructured":"Tsioutis C, Eichel VM, Mutters NT. Transmission of Klebsiella Pneumoniae carbapenemase (KPC)-Producing Klebsiella pneumoniae: the role of infection control. J Antimicrob Chemother. 2021;76:i4\u201311. https:\/\/doi.org\/10.1093\/jac\/dkaa492.","journal-title":"J Antimicrob Chemother"},{"key":"2608_CR30","doi-asserted-by":"publisher","first-page":"i47","DOI":"10.1093\/jac\/dkaa497","volume":"76","author":"U Theuretzbacher","year":"2021","unstructured":"Theuretzbacher U, Carrara E, Conti M, Tacconelli E. Role of new antibiotics for KPC-Producing Klebsiella Pneumoniae. J Antimicrob Chemother. 2021;76:i47\u201354. https:\/\/doi.org\/10.1093\/jac\/dkaa497.","journal-title":"J Antimicrob Chemother"},{"key":"2608_CR31","doi-asserted-by":"publisher","unstructured":"Marino A, Stracquadanio S, Campanella E, Munaf\u00f2 A, Gussio M, Ceccarelli M, Bernardini R, Nunnari G, Cacopardo B. Intravenous fosfomycin: A potential good partner for cefiderocol. Clinical experience and considerations. Antibiot (Basel). 2022;12. https:\/\/doi.org\/10.3390\/antibiotics12010049.","DOI":"10.3390\/antibiotics12010049"},{"key":"2608_CR32","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jinf.2018.02.007","volume":"76","author":"JA Ramos-Casta\u00f1eda","year":"2018","unstructured":"Ramos-Casta\u00f1eda JA, Ruano-Ravina A, Barbosa-Lorenzo R, Paillier-Gonzalez JE, Salda\u00f1a-Campos JC, Salinas DF, Lemos-Luengas EV. Mortality due to KPC Carbapenemase-Producing Klebsiella Pneumoniae infections: systematic review and Meta-Analysis: mortality due to KPC Klebsiella Pneumoniae infections. J Infect. 2018;76:438\u201348. https:\/\/doi.org\/10.1016\/j.jinf.2018.02.007.","journal-title":"J Infect"},{"key":"2608_CR33","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1017\/ice.2017.197","volume":"38","author":"PP Kohler","year":"2017","unstructured":"Kohler PP, Volling C, Green K, Uleryk EM, Shah PS, McGeer A. Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella Pneumoniae bacteremia: A systematic review and Meta-Analysis. Infect Control Hosp Epidemiol. 2017;38:1319\u201328. https:\/\/doi.org\/10.1017\/ice.2017.197.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2608_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s40121-021-00408-8","volume":"10","author":"AE Maraolo","year":"2021","unstructured":"Maraolo AE, Corcione S, Grossi A, Signori A, Alicino C, Hussein K, Trecarichi EM, Viale P, Timsit J-F, Veeraraghavan B, et al. The impact of carbapenem resistance on mortality in patients with Klebsiella Pneumoniae bloodstream infection: an individual patient data Meta-Analysis of 1952 patients. Infect Dis Ther. 2021;10:541\u201358. https:\/\/doi.org\/10.1007\/s40121-021-00408-8.","journal-title":"Infect Dis Ther"},{"key":"2608_CR35","doi-asserted-by":"publisher","first-page":"106611","DOI":"10.1016\/j.ijantimicag.2022.106611","volume":"60","author":"G Tiseo","year":"2022","unstructured":"Tiseo G, Brigante G, Giacobbe DR, Maraolo AE, Gona F, Falcone M, Giannella M, Grossi P, Pea F, Rossolini GM, et al. Diagnosis and management of infections caused by Multidrug-Resistant bacteria: guideline endorsed by the Italian society of infection and tropical diseases (SIMIT), the Italian society of Anti-Infective therapy (SITA), the Italian group for antimicrobial stewardship (GISA), the Italian association of clinical microbiologists (AMCLI) and the Italian society of microbiology (SIM). Int J Antimicrob Agents. 2022;60:106611. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106611.","journal-title":"Int J Antimicrob Agents"},{"key":"2608_CR36","doi-asserted-by":"publisher","first-page":"e0260321","DOI":"10.1128\/spectrum.02603-21","volume":"10","author":"Y Chen","year":"2022","unstructured":"Chen Y, Huang H-B, Peng J-M, Weng L, Du B. Efficacy and safety of Ceftazidime-Avibactam for the treatment of Carbapenem-Resistant enterobacterales bloodstream infection: A systematic review and Meta-Analysis. Microbiol Spectr. 2022;10:e0260321. https:\/\/doi.org\/10.1128\/spectrum.02603-21.","journal-title":"Microbiol Spectr"},{"key":"2608_CR37","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious diseases society of America 2024 guidance on the treatment of Antimicrobial-Resistant Gram-Negative infections. Clin Infect Dis. 2024;ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"2608_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","volume":"7","author":"RG Wunderink","year":"2018","unstructured":"Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, et al. Effect and safety of Meropenem-Vaborbactam versus Best-Available therapy in patients with Carbapenem-Resistant Enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018;7:439\u201355. https:\/\/doi.org\/10.1007\/s40121-018-0214-1.","journal-title":"Infect Dis Ther"},{"key":"2608_CR39","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2019.12.009","volume":"22","author":"Y Wang","year":"2020","unstructured":"Wang Y, Wang J, Wang R, Cai Y. Resistance to Ceftazidime-Avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18\u201327. https:\/\/doi.org\/10.1016\/j.jgar.2019.12.009.","journal-title":"J Glob Antimicrob Resist"},{"key":"2608_CR40","doi-asserted-by":"publisher","first-page":"e00447","DOI":"10.1128\/aac.00447-22","volume":"66","author":"CA Hobson","year":"2022","unstructured":"Hobson CA, Pierrat G, Tenaillon O, Bonacorsi S, Bercot B, Jaouen E, Jacquier H, Birgy A. Klebsiella Pneumoniae carbapenemase variants resistant to Ceftazidime-Avibactam: an evolutionary overview. Antimicrob Agents Chemother. 2022;66:e00447\u201322. https:\/\/doi.org\/10.1128\/aac.00447-22.","journal-title":"Antimicrob Agents Chemother"},{"key":"2608_CR41","doi-asserted-by":"publisher","first-page":"e02097","DOI":"10.1128\/AAC.02097-16","volume":"61","author":"RK Shields","year":"2017","unstructured":"Shields RK, Chen L, Cheng S, Chavda KD, Press EG, Snyder A, Pandey R, Doi Y, Kreiswirth BN, Nguyen MH, et al. Emergence of Ceftazidime-Avibactam resistance due to Plasmid-Borne blaKPC-3 mutations during treatment of Carbapenem-Resistant Klebsiella Pneumoniae infections. Antimicrob Agents Chemother. 2017;61:e02097\u201316. https:\/\/doi.org\/10.1128\/AAC.02097-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"2608_CR42","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14787210.2021.1976145","volume":"20","author":"M Gatti","year":"2022","unstructured":"Gatti M, Viaggi B, Rossolini GM, Pea F, Viale P. An Evidence-Based multidisciplinary approach focused at creating algorithms for targeted therapy of Infection-Related ventilator associated complications (IVACs) caused by enterobacterales in critically ill adult patients. Expert Rev Anti Infect Ther. 2022;20:331\u201352. https:\/\/doi.org\/10.1080\/14787210.2021.1976145.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2608_CR43","doi-asserted-by":"publisher","unstructured":"O\u2019Jeanson A, Nielsen EI, Friberg LE. Therapeutic drug monitoring (TDM) of \u03b2-Lactam\/\u03b2-Lactamase inhibitor (BL\/BLI) drug combinations: insights from a pharmacometric simulation study. J Antimicrob Chemother. 2024;dkae375. https:\/\/doi.org\/10.1093\/jac\/dkae375.","DOI":"10.1093\/jac\/dkae375"},{"key":"2608_CR44","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1093\/jac\/dky082","volume":"73","author":"P Gaibani","year":"2018","unstructured":"Gaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, Pongolini S, Berlingeri A, Cristini F, Bartoletti M, et al. In vivo evolution of resistant subpopulations of KPC-Producing Klebsiella Pneumoniae during ceftazidime\/avibactam treatment. J Antimicrob Chemother. 2018;73:1525\u20139. https:\/\/doi.org\/10.1093\/jac\/dky082.","journal-title":"J Antimicrob Chemother"},{"key":"2608_CR45","doi-asserted-by":"publisher","unstructured":"Giddins MJ, Macesic N, Annavajhala MK, Stump S, Khan S, McConville TH, Mehta M, Gomez-Simmonds A, Uhlemann A-C. Successive emergence of Ceftazidime-Avibactam resistance through distinct genomic adaptations in blaKPC-2-Harboring Klebsiella Pneumoniae sequence type 307 isolates. Antimicrob Agents Chemother. 2018;62. https:\/\/doi.org\/10.1128\/aac.02101-17.","DOI":"10.1128\/aac.02101-17"},{"key":"2608_CR46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jgar.2023.03.012","volume":"33","author":"A Oliva","year":"2023","unstructured":"Oliva A, Al Ismail D, Arcari G, Miele MC, Casali E, Sacco F, Volpicelli L, De Angelis M, Mascellino MT, Cancelli F, et al. Ceftazidime\/Avibactam-Resistant Meropenem-Susceptible KPC-Producing Klebsiella Pneumoniae: analysis of cases and evaluation of in vitro activity of Fosfomycin-Containing combinations. J Global Antimicrob Resist. 2023;33:321\u20137. https:\/\/doi.org\/10.1016\/j.jgar.2023.03.012.","journal-title":"J Global Antimicrob Resist"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02608-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-025-02608-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-025-02608-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:12:56Z","timestamp":1781604776000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-025-02608-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2608"],"URL":"https:\/\/doi.org\/10.1007\/s15010-025-02608-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the local Ethical Committees (no. 101\/CECT2; no. 0069\/2022 and 0341\/2023). The study was conducted according to the guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was waived due to the retrospective nature of the research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}